DeCure for Ectodermal dysplasia and immunodeficiency 1
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for ectodermal dysplasia and immunodeficiency 1 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEctodermal dysplasia and immunodeficiency 1 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ectodermal dysplasia and immunodeficiency 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glucose-6-phosphate dehydrogenase (G6PD) — G6PD is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet napdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6E08 · 1.9 Å · ligand NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NAP). Experimental structure, not a prediction.
What the evidence adds up to
Ectodermal dysplasia with immunodeficiency 1 is one of more than 170 distinct ectodermal dysplasia conditions, but as of 2000 fewer than a handful of causative genes had been identified across the entire group. The 2020 abstract specifies that hypomorphic variants in IKBKG and N-terminal variants in NFKBIA cause X-linked and dominant forms of ectodermal dysplasia with combined immunodeficiency, respectively. Biallelic loss of IKBKB, the gene coding IKKβ, causes a severe combined immunodeficiency. No abstract reports a clinical trial or treatment outcome for this specific disease.
A 2009 perspective article discusses gene therapy and protein therapy for ectodermal dysplasias in general, noting both successes and failures of these approaches, but provides no concrete survival or response rates. The article argues that a molecular-based classification is needed before such therapies can be rationally applied, and it does not describe any completed human trial for any ectodermal dysplasia subtype.
What is missing is any clinical trial data for ectodermal dysplasia and immunodeficiency 1 specifically. No abstract reports a tested drug, a measured response rate, or a survival outcome. The field lacks a molecular classification that would allow patient stratification, and no funding for a dedicated trial in this rare immunodeficiency is mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 2000 · 106 citations
Ectodermal dysplasias: not only ‘skin’ deep
AbstractThe ectodermal dysplasias (EDs) are a large and complex nosologic group of diseases; more than 170 different pathologic clinical conditions have been identified. Despite the great number of EDs described so far, few causative genes have been identified. We review EDs in the light of the most recent molecular findings and propose a new classification of EDs integrating both molecular-genetic data and corresponding clinical findings of related diseases.
Journal of Allergy and Clinical Immunology · 2020 · 11 citations · open access
Heterozygous IKKβ activation loop mutation results in a complex immunodeficiency syndrome
AbstractThe importance of NF-κB to human immune signaling is demonstrated by the large number of monogenetic diseases that arise from defects in the NF-κB subunits and the proteins that regulate them. Hypomorphic variants in IKBKG and N-terminal variants in NFKBIA cause X-linked and dominant ectodermal dysplasia with combined immunodeficiency (EDA-ID), respectively. Biallelic loss of IKBKB (the gene coding the protein IKKβ) causes a severe form of combined immunodeficiency. Monoallelic deficiency of individual NF-κB subunits is associated with common variable immunodeficiency and autoimmunity, and defects in proteins that carry out posttranslational modifications of NF-κB pathway proteins cause immunodeficiency, severe inflammatory disease, or both.
American Journal of Medical Genetics Part A · 2009 · 3 citations · open access
Gene therapy and protein therapy of ectodermal dysplasias: A perspective
AbstractEctodermal dysplasias (EDs) form a complex and heterogeneous group of diseases currently defined and classified according to their clinical symptoms. The characterization, for several EDs, of the molecular events underlying their development, not only challenges this classification but also opens the door to new therapeutic options such as gene or protein therapy. This article provides a concise overview of the most recent successes and failures of this new type of treatment and sets in perspective how the specificities of given EDs will influence their feasibility in the near future. It makes the case for the need of new classification of EDs that is based on our most recent knowledge of the molecular basis of these diseases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
